Exchange: NASDAQ·Updated 07:53 PM EDT
News
all
press releases
Xencor Reaches Analyst Target Price
In recent trading, shares of Xencor, Inc (Symbol: XNCR) have crossed above the average analyst 12-month target price of $29.00, changing hands for $29.33/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuatio...
Nasdaq News: Markets
More News
Xencor (XNCR) Reports Q2 Loss, Beats Revenue Estimates
Xencor (XNCR) delivered earnings and revenue surprises of +64.63% and +337.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Xencor Reports Second Quarter 2026 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2026. We are excited to present XmAb819 results at ESMO this fall and...
Business Wire
Xencor to Receive $105 Million From Alexion to Resolve Ultomiris U.S. Royalty Matter
Xencor, Inc. (NASDAQ:XNCR) (Xencor), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced its agreement with Alexion Pharma International Operations Limited, an Irish limited company (Alexion), to resolve a...
Business Wire
Xencor (XNCR) Soars 16.9%: Is Further Upside Left in the Stock?
Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks
Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that results from a Phase 1 study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in advanced clear cell renal...
Business Wire
A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs
A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs PR Newswire SAN FRANCISCO, July 6, 2026 Issued on...
PR Newswire
The Biology Came First.
MindWalk Holdings Corp. (NASDAQ: HYFT) today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at...
Business Wire
Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates
Xencor (XNCR) delivered earnings and revenue surprises of -164.58% and -75.38%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Xencor Reports First Quarter 2026 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the...
Business Wire

Advertisement|Remove ads.